Today, the global endocrine pharmaceutical market is a highly lucrative multi-billion dollar business, but, can you confidently answer the following?
What endocrine diseases will be successful?
What endocrine diseases will lose out?
What area of endocrine do you need to invest in?
Which areas of endocrine do you need to avoid?
Who are the key players in the endocrine market?
How much is the total global endocrine market worth today and in the future?
What are the major changes to the endocrine market?
Are there any newcomer's of importance?
What is in the endocrine pipeline?
Know the answer to all these questions and much more in visiongains latest global endocrine pharmaceutical market report.

Visiongain values the total global endocrine market at $43.2bn in 2005, a growth of 13.5% from 2004. The endocrine diseases market is expected to grow over 100% over the forecast period, to produce revenues in 2010 of just under $70bn. Major changes of the market are expected over the forecast period, such as the arrival of insulin delivery technologies and massive losses of the hypothyroidism market due to increasing generic competition.

For in-depth analysis of these changes it is vital that you purchase Endocrine 2005. Designed as an essential business aid, Endocrine 2005 provides a thorough evaluation of the market for you to keep ahead of your competitors.

Learn about the four therapeutic area major earners of the industry:

1) Hypertension
2) Diabetes
3) Osteoporosis
4) Infertility

In addition, Endocrine 2005 also features market analysis of the following:

- Growth Hormone Replacement
- Acromegaly
- Hypothyrodism and Hyperthyrodism

Why You Must Buy This Report
This 170+ paged report features 50+ tables, 20+ graphs and 20+ charts, news, insights, the very latest developments and an in-depth review of the endocrine market with up to date analysis. This report is a vital addition to gaining an understanding of this lucrative area of the pharmaceutical market, and will give your company 'the edge' of your competitors. You can not afford to be without this latest report from visiongain.